September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Evaluation of the efficacy of the one-piece fluocinolone acetonide (Retisert™) implant in chronic posterior and panuveitis
Author Affiliations & Notes
  • Thomas H Dohlman
    Ophthalmology, Weill Cornell Medical College, New York, New York, United States
  • Sarju S Patel
    Ophthalmology, Weill Cornell Medical College, New York, New York, United States
  • Footnotes
    Commercial Relationships   Thomas Dohlman, None; Sarju Patel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1877. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Thomas H Dohlman, Sarju S Patel; Evaluation of the efficacy of the one-piece fluocinolone acetonide (Retisert™) implant in chronic posterior and panuveitis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1877.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Posterior and pan-uveitis are vision-threating conditions that can be treated with intravitreal fluocinolone acetonide (Retisert™) implants. Recently, the implant was redesigned into a one-piece platform given complications of the two-piece implant over time. There is clinical suspicion that the one-piece design may be less efficacious in treatment compared to the two-piece design. Here we performed a retrospective case series evaluating the efficacy of one piece implants.

Methods : Eyes of patients with chronic posterior and pan-uveitis who received a one-piece fluocinolone acetonide implant (0.59 mg) were identified. To be included, the study eyes must have had at least 12 months of follow-up. Treatment efficacy was evaluated by assessing 1) the number of uveitis recurrences (defined according to published criteria by the SUN Working Group) and 2) the need for adjunctive therapy to control the uveitis. Percentages and proportions were calculated and compared to published data evaluating the original two-piece implant.

Results : 11 eyes of 6 patients were identified for inclusion. Zero eyes receiving the one-piece fluocinolone acetonide implant met the definition of a recurrence of uveitis. However, 6 eyes (55%) of 4 (66%) one-piece implant recipients required additional therapy (periocular injections and/or systemic therapy) to completely control the uveitis. 5 eyes (45%) of 3 (50%) implant recipients required adjunctive systemic therapy. These rates are considerably higher than previously published data on the original two-piece fluocinolone acetonide implant, in which 20% (MUST trial research group. Ophthalmology. 2015), 10.4% (Jaffe. Ophthalmology. 2011) and 13.9% (Sangwan Ophthalmol Ther. 2015) of two-piece implant recipients required systemic adjunctive therapy.

Conclusions : The one-piece fluocinolone acetonide implant, while highly active, may be less effective in treating chronic posterior and pan-uveitis when compared to the original two-piece design. This pilot study demonstrates a need for additional systemic anti-inflammatory therapy to fully control disease compared to previously published data. Larger studies are needed to evaluate this finding, as it may affect the use of the one-piece implant as a monotherapy and lower the threshold to employ additional anti-inflammatory therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×